Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:04 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:04 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Lantheus Holdings (LNTH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for May 31st
by Zacks Equity Research
MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.
Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?
by Zacks Equity Research
Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility
by Zacks Equity Research
Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
by Shaun Pruitt
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Lantheus Holdings (LNTH) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.
Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock
by Zacks Equity Research
Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
Lantheus Holdings (LNTH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Lantheus Holdings (LNTH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 9.03% and 5.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today
by Zacks Equity Research
The latest trading day saw Lantheus Holdings (LNTH) settling at $65.56, representing a +0.55% change from its previous close.
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) reachead $65.21 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.